Background: For inoperable non-small cell lung cancer combined chemotherapy and radiotherapy plays an important role as a therapeutic modality. The aim of the present study was to analyze neoadjuvant chemotherapy related acute toxicity in locally advanced lung cancer (stage IIIA and IIIB) in Indian patients using Cisplatin and Etoposide combination chemotherapy.
INTRODUCTION
molecules this regimen is useful since its therapeutic efficacy is proven and it is afforded by Locally advanced lung cancer is a challenge to the a majority of our patients coming from a poor socio treating physician not only due to poor response economic strata. to treatment but also due to treatment related morbidities. It is the leading site of cancer in males Treatment related toxicities are a major concern in three urban cancer registries of India. In males as it often leads to interrupted treatments and poor the AAR ranges from 1.36 -15.55. Females show a quality of life for patients. The aim of this present lower incidence rate with AAR ranging from 0.98-study was to study the chemotoxicity profile in 4.40. [1] Cancer registries even in younger 20 -24 Indian patients on Cisplatin and Etoposide year age group have recorded cases of lung cancer chemotherapy. but peak age specific rates are seen in seventh and eighth decade of life. Non-small cell lung cancer MATERIAL AND METHODS accounts for 75 -80 % of all neoplasms of lung. [2] Majority of these patients are inoperable and Forty patients of Locally Advanced Non -small Cell constitute the locally advanced cancer group. These Lung cancer were studied from January 2003 to patients are potential candidates for systemic December 2004 in this prospective trial. After chemotherapy alone or along with radiotherapy. [3] history taking and clinical examination the patients They are usually managed by neoadjuvant underwent baseline investigations including chemotherapy followed by radiotherapy and complete haemogram and biochemistry profile. treatment maybe associated with a variety of side Chest X-Ray And CT scan evaluation was done. effects. [4] One such Neoadjuvant chemotherapy Bronchoscopic evaluation was done and biopsy regimen using Injection Cisplatin and Injection taken. Mediastinoscopy evaluation of nodal staus Etoposide has been used in trials due to its was done where indicated. CT scan of abdomen was synergistic action. [5] Cisplatin was given in a dose of 100mg/m² in three divided doses from day one to day three. Injection Etoposide was used in a dose of 100mg/m²/day from day one to day three. The chemotherapy cycles were repeated at three weekly intervals. The patients were evaluated for Acute Toxicity of chemotherapy twice a week. Common toxicity criteria (CTC version 2.0) was used for toxicity grading. At the end of three cycles of chemotherapy the patients were evaluated by repeat CT scan of chest and abdomen and taken up for definitive radiotherapy where indicated up to a dose of 60 Gray over 30 fractions in conventional fractionation.
RESULTS
The median age of presentation of patients in the study was fifty-six years. There were thirty-two male and eight female patients. Thirteen patients suffered from Non-small cell lung cancer stage IIIA and twenty-seven patients had stage IIIB disease. Squamous cell carcinoma was the most common histology [78%]. 74% patients were smokers with a mean duration of smoking of thirteen years. Cough and chest pain were the most common presenting symptoms in 89% of patients. All forty patients completed three cycles of neoadjuvant chemotherapy and were available for evaluation. The toxicity seen is tabulated in [ Table 1 ].
Hematological toxicity: Anemia was the most common hematological toxicity observed (81% of patients). At end of second cycle of chemotherapy Grade 1 anemia was observed in 39.4% of patients and 26.3% had grade 2 anemia. One patient developed Grade 3 anemia. After third cycle of chemotherapy, 40 % of patients developed grade 1 anemia while 27% had grade 2 anemia. 13.5% patients had Grade 3 anemia. of patients while grade 2 was seen in45.9% of patients.
54 % experienced Grade 1 weight loss after first cycle while 21% had grade 2 weight loss after second cycle of chemotherapy. At the end of third cycle 33% had Grade 1 weight loss while 63.8% developed a Grade2 weight loss.
Febrile Neutropenias. Seven patients had febrile neutropenias with no mortality.
No hepatotoxicty was observed nor were any allergic reactions noted.
Overall response was assessed using response evaluation criteria in solid tumors (RECIST 
DISCUSSION
The rationale of using neoadjuvant chemotherapy in locally advanced non-small cell lung cancer is to cause a decrease in the tumor bulk before instituting radiotherapy. A variety of chemotherapy related toxicity is observed in patients on such regimens. In our study we observed anemia in 81% of patients making it the most common hematological toxicity observed. The frequency of hematological toxicity increased from from cycle one to cycle three. Grade 3 anemia was seen in13.5% of patients after third cycle of chemotherapy. Jean Pujol et al observed Grade 3-4 anemia in 18 % of patients treated by cisplatin, etoposide and Ifosfamide. [4] Leucopenia (Grade 1 3) was seen in 63.8 % of our patients. Studies have shown an incidence of leucopenia upto 54%. [6] We observed thrombocytopenia in 44.44% patients after third cycle of treatment. 97.2% of patients on treatment experienced nausea after second cycle of chemotherapy. Majority of these were Grade 1 nausea. Almost all patients experienced vomiting during second and third cycles of chemotherapy. Grade 1 vomiting was seen 48.6% of patients while grade 2 vomiting was seen in 45% of patients after second cycle of chemotherapy. Nausea and vomiting was seen despite standard antiemetic therapy. An incidence of Grade 1 vomiting of 21.4% to 28% has been observed in different studies. [7] Sensory neuropathy was observed in 38 % of patients after third cycle of chemotherapy. Out of these 33.3% of patients had grade 1 sensory neuropathy.
Albain et al [8] observed grade 1 neurological toxicity in 21.42 % of patients. Other studies have shown an incidence of 20.5%for sensory neuropathy. [9] Five patients under study had a grade 1-2 increase in creatinine clearence. A 15 -23% incidence of grade 1 increase in creatinine clearence has been shown in various studies. [6, 7] No renal failures were observed in our study. Shepherd [2] has observed that less than 10 % patients achieve complete response to induction chemotherapy (range 0-23%). We observed a complete response in 5.26% patients.
Hematologoical toxicity were managed using blood transfusion, growth factors like Filgrastim 5mcg/kg, along with antibiotic support where indicated. Dose modification of chemotherapy may be needed in some of our patients due to poor chemotolerance. The above measures practiced judiciously were able to tide over most of the events quite effectively.
CONCLUSIONS
Treatment related toxicities not only cause limitation in quality of life of patients but also cause interruptions of the proposed therapeutic regimen. Hematological toxicity was the major concern using Cisplatin and Etoposide regimen. The toxicity is effectively controlled using conservative measures.
Cisplatin and Etoposide continue to be an effective regimen for treating locally advanced lung cancer in Indian patients.
